Allo-SCT has a strong curative potential for AML patients mainly due to a GVL effect. Unfortunately, GvL and GVHD are intimately linked. IFN regulatory factor-3 (IRF3), by modulating innate immune reactions, could impact on the incidence and intensity of GVL and GVHD. We analyzed two gene variants in IRF3 (rs7251 and rs2304205) on the clinical outcome of 249 AML patients submitted to HLA-identical sibling allo-SCT. Patients with a donor carrying the dominant GG gene variant in rs7251 had, as compared with GC and CC variants, a lower acute GVHD (aGVHD) III-IV incidence (4% vs 11% vs 27%; P ¼ 0.0078), a higher relapse incidence (49% vs 35% vs 26%; P ¼ 0.018), and lower TRM (7% vs 24% vs 18%; P ¼ 0.0065). In functional studies, the GG variant was associated with lower production of IFN-g, decreased lymphocyte proliferation after antigen presentation by DCs, and lower cytotoxic response of mature natural killer cells. Patients carrying the AA dominant variant in rs2304205 had higher relapse incidence (50% vs 39% vs 18%, P ¼ 0.0068). The presence of both variants (GG in rs7251 and AA in rs2304205) in donors and patients resulted in a stronger clinical impact.
INTRODUCTION
Each year the number of allo-SCT held in Europe is higher than previous years, 1,2 AML being the most frequent indication for allo-SCT. 2 One of the main reasons is the proven curative effect of the GVL 2-4 associated to allo-SCT. Unfortunately, GVL effect and GVHD, are intimately linked. Thus, it is important to identify markers predictive of severe GVHD, to balance the risk of this complication and the risk of relapse in a particular AML patient.
After allo-SCT, GVHD and GVL depend on donor T-cell recognition of host antigens presented by recipient DCs. 5 Current data implicate not only the adaptive immune system, but also the innate immune system as being responsible for initiating or amplifying GVHD and GVL effect. It is known that molecules released from dying cells through necrosis are highly pro-inflammatory. Thus, in the allo-SCT context, molecules known as damage-associated molecular patterns, 6 which are released following the conditioning regimen, have a key role in the induction of GVHD 7, 8 by activating innate immune receptors, mainly toll-like receptors (TLR), and causing cytokine storm. 6, 9, 10 The interferons are key molecules orchestrating this immune response. 11 Thus, after infectious or non-infectious injury stimulation, TLR3 and TLR4 initiate TLR adaptor TICAM-1 (TRIF)-dependent stimulus to activate intracellular signaling cascades that converge on NF-kappaB and IFN regulatory factor-3 (IRF3) activation, inducing production of pro-inflammatory cytokines. [12] [13] [14] [15] Besides, IRF3 activation through TRIF signaling in BM-derived DCs results in natural killer (NK) cell activation by direct cell-cell contact inducing an antitumor NK response. 16, 17 We and others have previously analyzed the clinical impact of gene polymorphisms of the innate immune system on the outcome of allo-SCT. [18] [19] [20] [21] Owing to the importance of IRF3 in the inflammatory response we hypothesized that genetic variability in IRF3 in either the donor or recipient could impact on the degree of the inflammatory response and of the alloimmune response mediated by inflammatory cytokines, DCs and by antitumor NK cells, influencing the GVHD incidence and/or GVL after allo-SCT. Thus, the aim of this study was to analyze the effect of two frequent single-nucleotide polymorphisms (SNPs) in IRF3, which are inherited in a haplotype, on GVHD and GVL in a group of 249 patients diagnosed with AML and submitted to HLAidentical sibling allo-SCT.
MATERIAL AND METHODS

Study population
Study population consisted of 249 donor-patient pairs from the Spanish Group of Bone Marrow Transplantation (GETH) receiving HLA-identical sibling allo-SCT between 1997 and 2010 (Table 1 ). All patients were diagnosed with AML. Patients (64.3%) were in first or second CR (RC1 and RC2, respectively) and 28.9% were in 4RC2 or in active disease. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki.
Genotyping Assay (Applied Biosystems, Foster City, CA, USA). Reactions were performed as previously reported. 18 According to the frequencies obtained for rs7251 gene variant and for rs2304205 gene variant GG, GC and CC; and AA, AC and CC were classified as the homozygous dominant, heterozygous and homozygous recessive gene variants, respectively for each gene variant.
Functional studies in healthy individuals
Inflammatory response, lymphocyte proliferation after antigen presentation by DCs, cytotoxic activity of NK cells and specific IFN-g production by lymphocytes after viral and inflammatory stimuli were determined according to the presence of rs7251 and rs2304205 in IRF3 in 180 healthy donors. The detailed methodology is described in the on-line Supplementary material.
RNA isolation and gene expression analysis
Analysis was performed in 56 healthy individuals to determine if the presence of SNPs in IRF3 influenced mRNA expression of IRF3 and of genes involved in the inflammatory response (HAMP, MIF, PTX3), cell cycle (AURKB, CCNA2, CCNB1, CCND3), lymphocyte survival (NFAT5, SLC38A2, SLC6A6) and P53. RNA isolation was performed as previously described. 22 Real-time PCR is described in the on-line Supplementary material. Relative mRNA expression was determined using the 2 ( À DDCt) method according to Schmitt and Livak. 23 
Data analysis
For each allo-SCT, analysis was performed according to donor and patient genotype performing the analysis first in the three different genotype groups for the two SNPs, and afterwards in two groups according to the presence or absence in homozygosis of the homozygous dominant gene variants in both SNPs. Five clinical end points were considered: aGVHD grades II-IV and III-IV (aGVHD II-IV/III-IV), relapse, TRM, disease-free survival, and OS. aGVHD II-IV/III-IV, relapse and TRM were analyzed using the Fine and Gray test. Cumulative incidence was computed with the cmprsk package for R 2.9.2 software (The R Foundation for Statistical Computing, Vienna, Austria). 24 For aGVHD II-IV/III-IV the competing event was death and for relapse the competing event was death in remission. For TRM the competing event was relapse. Disease-free survival and OS were obtained by Kaplan-Meier method and compared using log-rank test. P-values were two-sided and significance was considered with Pp0.05. Variables included at univariate analysis were genotype for the two SNPs in IRF3, patient age (45 years was the cutoff value considered), donor/patient gender matching (female donor into male recipient vs others), source of stem cells (peripheral blood vs BM), type of conditioning (myeloablative vs reduced intensity) and advanced phase of disease (RC1 þ RC2 vs 4RC2 or in active disease). Multivariate analysis was performed adding gene variants in IRF3 and incorporating those clinical variables with a P-value p0.1 in the univariate analysis. Multivariate analysis of disease-free survival and OS was performed using Cox regression with forward method and Wald statistic (SPSS 15.0; Chicago, IL, USA). Multivariate analysis of aGVHD II-IV/III-IV, relapse and TRM was performed using the subdistribution regression model of Fine and Gray with the cmprsk package (R 2.9.2 software). The proportional hazard assumption was tested for each variable by graphical methods according to Andersen et al. 25 Analysis of Hardy-Weinberg equilibrium was analyzed by Fisher's exact test. 
Abbreviations: CR1 ¼ first CR; CR2 ¼ second CR; HPC ¼ hemopoietic progenitor cells; IRF3 ¼ IFN regulatory factor; PB ¼ peripheral blood; RIC ¼ reduced intensity-conditioning regimen. P-value represents comparison between groups with GG vs GG and CC in rs7251 in IRF3.
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RESULTS
GG dominant gene variant in rs7251 in
IRF3 associates with lower IFN-g serum production, lower mature NK cells activity and lower lymphocyte proliferation, and AA dominant gene variant in rs2304205 with lower IRF3 and MIF expression Frequencies of the GG, GC and CC genotypes in rs7251 in IRF3 among 180 healthy individuals analyzed were: GG ¼ 45.6%, GC ¼ 42.2% and CC ¼ 12.2%. Functional studies showed that after stimulation of peripheral blood with CMV peptides, those individuals carrying GG gene variant in rs7251 presented lower IFN-g serum production than the rest ( Figure 1a ). We did not find any other association in the rest of cytokines analyzed. When the results were studied according to the serological status for CMV, it was observed that in seronegative CMV individuals, after stimulation with CMV peptides, GG gene variant in rs7251 was associated with lower number of IFN-g producing mature NK cells (CD56dim CD16 þ ) (Figure 1b) , and with lower number of cytotoxic NK cells against K562 (Figure 1c) . Further, GG gene variant in rs7251, as compared with GC and CC variants, was associated with lower proliferation of T cells after antigen presentation by DCs (Figure 1d ). rs2304205 AA gene variant in IRF3 in blood of healthy individuals was not associated with any change in the cytokine production. However, rs2304205 AA gene variant in IRF3 was associated with a lower IRF3 expression, lower MIF expression (a key mediator of the innate immune response), and lower expression of CCNA2 and AURKB (genes involved in cell cycle) (Figure 2 ).
GG dominant gene variant in rs7251 in IRF3 impacts on a low incidence of acute GVHD III-IV, high relapse incidence, and low incidence of TRM Frequencies of GG, GC and CC genotypes in IRF3 rs7251 in donor and patient were: GG ¼ 45%, GC ¼ 44%, and CC ¼ 11%; and GG ¼ 43%, GC ¼ 42%, and CC ¼ 15%, respectively. Clinical risk factors associated with aGVHD II-IV/III-IV, relapse, TRM, diseasefree survival and OS at univariate analysis are shown in Table 2 .
Patients with a donor carrying dominant homozygous GG gene variant in rs7251 had, as compared with GC and CC variants, significantly lower aGVHD III-IV (4% vs 11% vs 27%; P ¼ 0.0078), higher relapse incidence (49% vs 35% vs 26%; P ¼ 0.018), and lower TRM (7% vs 24% vs 18%; P ¼ 0.0065) ( Table 2 , Figures 3a-c).
All these effects were retained at multivariate analysis (Table 3) . Further, when we analyzed the patients according to the conditioning regimen, similar results were obtained in both reduced intensity-conditioning regimen and myeloablative conditioning subgroups (Supplementary Table 1 ). The GG variant in rs7251 when present in patients was also associated with a lower aGVHD III-IV (4% vs 13% vs 24%; P ¼ 0.009), higher relapse incidence (50% vs 34% vs 31%; P ¼ 0.014), and with a trend for a lower TRM incidence (9% vs 19% vs 23%; P ¼ 0.064) ( Table 2) . However, at multivariate analysis, GG in rs7251 in patients did not retain the clinical impact (data not shown).
AA dominant gene variant in rs2304205 in IRF3 and relapse incidence At genotyping analysis, frequencies of AA, AC and CC genotypes in rs2304205 in IRF3 rs2304205 in donor and patient were: AA ¼ 59%, AC ¼ 32% and CC ¼ 9%; and AA ¼ 51%, AC ¼ 39% and CC ¼ 10%, respectively. Patients carrying AA dominant gene variant in rs2304205 in IRF3 presented higher relapse incidence than the rest of genotypes (AA ¼ 50% vs AC ¼ 39% vs CC ¼ 18%, P ¼ 0.0068). However, this impact was not retained at multivariate analysis (data not shown).
Clinical effect of GG in rs7271 and AA in rs2304305 in IRF3 when present together As rs2304205 in IRF3 is inherited in a haplotype with rs7251 (GG in rs7251 and AA in rs2304205 were present together in 48.25% of the patients), we analyzed the impact of both variants classifying the pairs of donors and patients in four groups according to:
(1) presence of both dominant gene variants (GG in rs7251 and AA in rs2304205) in donor and patient (donor and recipient harboring The presence of GG and AA gene variants in both donor and patient was associated with a very low incidence of aGVHD III-IV (2.2% vs 2.7% vs 4.7% vs 18%, P ¼ 0.037, respectively for the four different groups), with a high relapse incidence (59% vs 55% vs 43% vs 29%, P ¼ 0.00047, respectively for the four different groups) and with low TRM (4% vs 13% vs 15% vs 22%, P ¼ 0.01, respectively for the four different groups) ( Table 2 ). This impact was retained at multivariate analysis only for relapse (P ¼ 0.007, odds ratio ¼ 1.96) and TRM (P ¼ 0.04, odds ratio ¼ 4.45) (data not shown).
DISCUSSION
IRF3 has an important role in the inflammatory response mediated by the innate immune system, in particular in the activation of inflammatory responses initiated by DCs and in antitumoral responses mediated by NK cells, which may both trigger alloresponses. 16, 17 These roles make IRF3 a potential target to study in the context of the alloreactivity after allo-SCT. This study suggests that a common genetic IRF3 variant (GG in rs7251, present in 45% of Caucasians) in donors and in less degree in patients, is associated in healthy individuals with a low inflammatory response, with a decreased lymphocyte proliferation after antigen presentation by DCs, and also with a low cytotoxic response of mature NK cells. Of note, this common genetic variant in IRF3 might be associated with a low incidence of severe aGVHD and low TRM, and with a high incidence of relapse in patients diagnosed with AML and submitted to HLA-identical sibling allo-SCT. GG in rs7251 IRF3, coding for a missense change, might alter the interaction of IRF3 with the downstream genes in these inflammatory pathways.
In this series of AML patients submitted to allo-SCT, an association between a low incidence of severe aGVHD and a high incidence of relapse was observed, as recently reported by the European Group for Blood and Marrow Transplantation (EBMT) in a series of AML patients submitted to reduced intensity conditioning allo-SCT. 26 Here, it was also found that the group of patients with low incidence of severe aGVHD had low incidence of TRM. Unfortunately, the low incidence of severe aGVHD had no net impact on OS because the lower TRM in patients with no severe aGVHD was offset by a higher risk of relapse, as observed by other groups of investigators. [26] [27] [28] [29] These findings highlight the well-known relationship between these two allo-immune reactions, GVHD and GVL effect, in allo-SCT setting, and the difficulty to dissociate both. We found that GG in rs7251 IRF3, associated with a decreased inflammatory and allo-immune response in the functional studies, affected to the incidence of GVHD (decreased) and of relapse (increased), with no apparent more pronounced effect on one respect to the other.
We observed a low IFN-g production in those healthy controls carrying GG in rs7251 IRF3. The pro-inflammatory cytokine IFN-g is a major contributor to GVHD. Thus, IFN-g is a potent inducer of indoleamine 2, 3 dioxygenase, which has an important role increasing GVHD incidence. 30 The major GVHD and GVL effectors are cytotoxic T cells that recognize allogeneic histocompatibility antigens and unique tumor antigens. In this context, we found in healthy controls that GG in rs7251 IRF3, as compared with GC and CC variants, was associated with lower proliferation of T cells after antigen presentation by DCs. Either the lower activity of DCs in cells of the patient or the lower T-cell proliferation in cells of the donor could explain the lower aGVHD incidence found for this variant when present in both the donor and patient. In addition to the role of T cells in the GVL effect, NK cells can directly recognize MHC class I molecules and stress-induced peptides and mount antitumor responses. [31] [32] [33] IRF3 has an important role in NK cell activation during inflammation. 16 We observed in healthy controls harboring GG in rs7251 IRF3 a low activity of mature NK cells, both after CMV stimulation and after coculture with K562 cells. The lower NK cell activity for this gene variant could also be explained by the lower NK cell activation by DCs. NK cell activity is mediated not only by a direct DC-NK cells contact but also by the production of IFN-g by DCs. 16, 34 In support of this, we observed Cumulative incidence (aGVHD II-IV, aGVHD III-IV, relapse, TRM) or actuarial probability (DFS and OS) values. P-values are in brackets. IRF3 gene variants and outcome in allo-SCT AML patients B Martín-Antonio et al low production of IFN-g and low mature NK cell activity in healthy controls with GG in rs7251 IRF3. NK cells, which are the first population to reconstitute after allo-SCT, 35 divide into two populations according to their maturation stage, and the mature NK cells are responsible for mediating a GVL effect in AML patients submitted to allo-SCT. 33 Besides, it has been shown that IFN-g protects against the development of both induced and spontaneous tumors in a variety of models. 36 Therefore, the observed higher relapse incidence in this series of patients when the donor harbored a GG rs7251 IRF3, might be due not only to the lower incidence of severe aGVHD and to a decreased lymphocyte proliferation after antigen presentation by DCs, but also to lower mature NK cell activity.
For the genetic variant AA in rs2304305, we did not find any association in the functional studies with the cytokine production or with the intensity of alloresponses as we found for GG in rs7251. However, we found that this variant was associated in healthy controls with lower IRF3 expression, probably due to the fact that AA in rs2304205 is present in the promoter region of IRF3. IRF3 overexpression in normal and in cancer cells mediates a p53-dependent inhibition of cell growth 37 and also leads to DC and NK cell activation. 16, 17 Lower IRF3 expression in AA rs2304305 in IRF3 could affect into a lower p53 expression leading to a lower inhibition of cell growth in leukemic cells of the patient. Besides, lower IRF3 expression in cells of the patient could induce lower DC activity impacting in a lower NK cell activity leading to lower aGVHD and lower GvL effect. The effects for this AA variant could increase the impact after allo-SCT when both variants (AA and GG) in IRF3 are together as it's observed in the clinical association. We also observed that AA in rs2304205 IRF3 was associated with lower MIF and cell cycle genes expression. MIF is the initial regulator of the inflammatory response, promoting inflammatory reactions and cell survival. [38] [39] [40] A lower MIF expression could also influence into lower inflammatory response and into lower lymphocyte proliferation. Altogether, the lower expression of IRF3, MIF and of cell cycle genes might impact in a higher relapse incidence, as suggested in the univariate analysis for patients carrying AA in rs2304205 IRF3.
In conclusion, we show that a particular gene variant in IRF3 in donors seems to be associated with low incidence of severe aGVHD and high incidence of relapse in AML patients submitted to allo-SCT. This particular clinical behavior associated with GG in rs7251 in IRF3 could be explained by its effect in the inflammatory and adaptive immune response. Gene polymorphisms in rs7251 in IRF3 are very prevalent, the clinical association of these genetic variants with GVHD and relapse in AML patients, if confirmed by other groups, might be taken into consideration when choosing the immunosuppressive regimen (for example, the use of ATG) or, in patients with high risk of relapse, the use of an unrelated donor if the related comes with an increased risk of impaired alloreactivity. If results of this study are also confirmed in the haploidentical setting, it might suggest that, if possible, when transplanting an AML patient with low risk of relapse after the transplant it might be preferable to select a donor harboring a GG in rs7251 in IRF3, and when transplanting an AML patient with high risk of relapse after the transplant it might be preferable to consider select a donor GC or CC in rs7251 in IRF3. IRF3 gene variants and outcome in allo-SCT AML patients B Martín-Antonio et al
